Full analysis #GLP1 #EmployeeBenefits #HealthcareCosts #WorkforceHealth #Aon Farheen Dam Doug Melton Lisa Stevens Laura Rissover Liz Parr Lindsay Dower, MHA Kembre Roberts, PhD Workforce-Focused Analysis on GLP-1s: Phase Two Findings aon.com To view or add a comment, sign in Novo Nordisks FDA-approved Wegovy pill, as highlighted by Ferrin Williams, PharmD MBA, marks a major shift in obesity careintroducing an oral GLP-1 option that could expand access, improve adherence, and reshape how clinicians manage chronic weight conditions
In terms of results , users of GLP-1 Elevate typically experience weight loss in the range of 8 to 14 pounds over 8 to 12 weeks, depending on diet and activity level
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, et al
Archived from the original on 2020-06-10
Systematic review across five major studies A systematic review pooling data from 2,905 patients across five studies found that 1.6% of the total GLP-1 patient population of 626,894 experienced some form of hair loss